GHK-Cu (copper peptide)

GHK-Cu (copper peptide) at a Glance

GHK-Cu is the copper complex of glycyl-L-histidyl-L-lysine, a tripeptide that occurs naturally in human plasma and declines steadily with age. The copper is not incidental — the peptide’s function is to carry and deliver it, and copper is a required cofactor for lysyl oxidase, the enzyme that crosslinks collagen and elastin. It is used topically for skin firmness and wound repair, and it is one of the better-established cosmetic peptide ingredients rather than a grey-market injectable.

History & Development

GHK-Cu is not a designed molecule. It is a copper-binding tripeptide already circulating in human plasma - and one that declines steadily with age, which is the whole basis of its use.

First described	Not established in the sources consulted for this section
Discovered / synthesised by	Not established in the sources consulted for this section
Institution	Not established in the sources consulted for this section
Origin	Endogenous human tripeptide glycyl-L-histidyl-L-lysine (Gly-His-Lys, MW ~340 Da) as its copper(II) complex
Key patent	Not established in the sources consulted for this section
Assignee	Not established in the sources consulted for this section
Development status	Established cosmetic ingredient (INCI copper tripeptide-1); the injectable form is an unapproved research chemical

Discovery

GHK occurs naturally in human plasma, and its concentration falls steadily with age - the observation that made it interesting, since declining levels of a repair-associated molecule is a tidy story about why skin heals less well over time.

The copper is not incidental. GHK’s function is inseparable from its ability to bind copper(II), delivering it in a controlled way to the enzymes that need it - including lysyl oxidase, which crosslinks collagen and elastin. GHK-Cu is best understood as a copper delivery system rather than a peptide that happens to carry a metal.

It has also been marketed under the trade names Lamin and Iamin.

Development & ownership

GHK-Cu’s position is unusual on this hub because its safety profile is bimodal by route.

As copper tripeptide-1 it is an established, legal topical cosmetic ingredient with decades of benign use, and the peptide is endogenous, so at cosmetic concentrations the exposure is unremarkable. That is the well-founded half.

The injectable form is an entirely different proposition: an unapproved research chemical, with no approval anywhere, and with copper as a consideration that does not arise topically - systemic copper loading has its own toxicity, and injecting a copper complex is not the same act as applying one to skin.

How it reached the market

The topical form reached the market as a cosmetic ingredient, requiring no pre-market approval. The injectable form reached it the way the rest of the grey market does - sold for skin, hair and wound repair on the strength of the topical and in-vitro record, by a route that record does not cover.

What It's Used For

GHK-Cu is the copper(II) complex of the human tripeptide glycyl-L-histidyl-L-lysine (GHK, sequence Gly-His-Lys, MW of the free peptide ≈ 340 Da) — a small copper-binding peptide that occurs naturally in human plasma, saliva and urine and declines with age (from roughly 200 ng/mL at age 20 toward ~80 ng/mL by age 60) ^{1,2Reference 1Pickart L · 2018ReviewRegenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data — reviewView study →Reference 2Pickart L et al. · 2015ReviewGHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration — reviewView study →}.

It was first isolated in 1973 as a serum factor that prolonged the survival of cultured liver cells, and its activity was later shown to depend on chelation of Cu²⁺ ^{9Reference 9Pickart L · 1973Tripeptide in human serum which prolongs survival of normal liver cells and stimulates growth in neoplastic liver — discoveryView study →}.

Of the peptides in this batch it has the most developed and most independently replicated evidence base, but the honest posture is still mechanism-and-cosmetic-first: the strongest data are in-vitro and ex-vivo human-skin studies of collagen/elastin synthesis and a large body of gene-expression work, while controlled human efficacy trials are few, small, and mixed — including a frankly null venous-ulcer trial ^{8Reference 8Bishop JB et al. · 1992RCTA prospective randomized evaluator-blinded trial of two potential wound healing agents for the treatment of venous stasis ulcers — RCT (human; null for copper tripeptide)View study →} and a cosmetic RCT that improved patient-reported but not objective outcomes ^{6Reference 6Miller TR et al. · 2006RCTEffects of topical copper tripeptide complex on CO₂ laser-resurfaced skin — randomised controlled trial (human)View study →}.

Route is central: GHK-Cu is used overwhelmingly topically (creams/serums), where skin penetration of the intact charged tripeptide is itself a debated limitation ^{22,24Reference 22Mortazavi SM et al. · 2025ReviewTopically applied GHK as an anti-wrinkle peptide: advantages, problems and prospective — reviewView study →Reference 24Mortazavi SM · 2022ReviewSkin permeability, a dismissed necessity for anti-wrinkle peptide performance — reviewView study →}; the injectable “research peptide” form sold online has essentially no human safety or efficacy characterization.

Evidence by IndicationStrength of support · Beta

Support is an experimental score I’m building — a composite weighted by study type (human > animal > in vitro > review) and study volume. It’s a beta: a fast way to rank strength of evidence at a glance, not a validated metric. For GHK-Cu the ceiling is set by the fact that the deepest data are mechanistic (in-vitro/ex-vivo) and the human efficacy data are thin and mixed — so even the top row sits mid-scale, with the human gap stated out loud. Each application links down to its write-up.

01Skin aging & cosmetic firmnessPromising46%Replicated in-vitro + ex-vivo human skin collagen/elastin/GAG data; long topical-cosmetic use; one small human RCT positive only on patient-reported outcomes

02Wound healingShaky40%Positive irradiated-rat & rabbit RCT models + strong remodeling mechanism; but a human venous-ulcer RCT was null; Phase 2 human trial now recruiting

03Pulmonary fibrosis & lung injuryShaky30%Multiple mouse models (bleomycin, LPS, silica) across more than one lab; anti-oxidant/anti-TGF-β1 mechanism; animal-only

04Anti-aging gene modulationShaky22%Connectivity-Map / in-silico gene-signature analyses + in-vitro; single-group, no human outcome

05Hair regrowthShaky20%One human AGA study, but copper peptides combined with minoxidil + dutasteride (confounded); otherwise marketing

06Neuroprotection & cognitionShaky18%In-silico nervous-system gene expression + review; no animal behavioral or human data

Mechanisms

Pharmacokinetics

Route and delivery are the decision-relevant facts. GHK-Cu is used almost entirely topically (creams, serums, and in trials a gel) ^{6,28Reference 6Miller TR et al. · 2006RCTEffects of topical copper tripeptide complex on CO₂ laser-resurfaced skin — randomised controlled trial (human)View study →Reference 28ClinicalTrials.gov · 2026RCTTopical GHK-Cu Gel for Acute Skin Wound Healing — Phase 2, randomised, placebo-controlled (recruiting; started Feb 2026). https://clinicaltrials.gov/study/NCT07437586View study →}; the copper complex improves the bioavailability and stability of the peptide relative to free GHK ^{12Reference 12Ma WH et al. · 2020AnimalProtective effects of GHK-Cu in bleomycin-induced pulmonary fibrosis via anti-oxidative stress and anti-inflammation pathways — mouseView study →}. Even topically, delivery is contested: as a small but charged, hydrophilic tripeptide, GHK penetrates the stratum corneum poorly and is susceptible to skin proteases, and reviews specifically flag skin permeability as a “dismissed necessity” for anti-wrinkle peptide performance — driving formulation work with penetration enhancers and encapsulation ^{22,24Reference 22Mortazavi SM et al. · 2025ReviewTopically applied GHK as an anti-wrinkle peptide: advantages, problems and prospective — reviewView study →Reference 24Mortazavi SM · 2022ReviewSkin permeability, a dismissed necessity for anti-wrinkle peptide performance — reviewView study →}. Endogenously, GHK circulates bound to copper (and iron) in plasma and its levels fall with age ^{1,9Reference 1Pickart L · 2018ReviewRegenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data — reviewView study →Reference 9Pickart L · 1973Tripeptide in human serum which prolongs survival of normal liver cells and stimulates growth in neoplastic liver — discoveryView study →}. There is no published human pharmacokinetic study (half-life, systemic clearance) for administered GHK-Cu; the free peptide is expected to be cleared rapidly and is subject to proteolysis. The injectable “research peptide” form is supplied as a lyophilized powder requiring reconstitution — but its human PK, like its safety, is uncharacterized (see Sourcing, Route & Legal Status).

Clinical & regulatory status

GHK-Cu is an approved and long-used cosmetic ingredient (topical creams/serums), but it is not an approved drug or dietary supplement for any therapeutic indication, and the injectable/systemic “research peptide” form is an unapproved research chemical sold “not for human consumption” with no regulatory oversight; recent peptide-therapy reviews group it with other unapproved “gray-market” regenerative peptides ^{27Reference 27Mendias CL et al. · 2026ReviewSafety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance — reviewView study →}. Registered-trial activity is limited but present: a Phase 2 randomized, placebo-controlled trial of topical GHK-Cu gel for acute cutaneous wounds (NCT07437586) began recruiting in 2026 ^{28Reference 28ClinicalTrials.gov · 2026RCTTopical GHK-Cu Gel for Acute Skin Wound Healing — Phase 2, randomised, placebo-controlled (recruiting; started Feb 2026). https://clinicaltrials.gov/study/NCT07437586View study →}, and a separate two-part study (NCT07706361) plans to measure whether a wearable patch changes circulating GHK/GHK-Cu levels in healthy adults ^{29Reference 29ClinicalTrials.gov (2027 · 2027Two-Part Study of the Effects of the X39 Patch on Circulating GHK and GHK-Cu Levels in Healthy Adults — not yet recruitingView study →}. The historical human evidence is a single small cosmetic RCT after laser resurfacing ^{6Reference 6Miller TR et al. · 2006RCTEffects of topical copper tripeptide complex on CO₂ laser-resurfaced skin — randomised controlled trial (human)View study →} and the 1992 venous-ulcer RCT ^{8Reference 8Bishop JB et al. · 1992RCTA prospective randomized evaluator-blinded trial of two potential wound healing agents for the treatment of venous stasis ulcers — RCT (human; null for copper tripeptide)View study →}. There is no completed registered efficacy trial with a positive controlled result for any systemic indication.

Last checked: July 2026.

Sourcing, Route & Legal Status

Regulatory status — cosmetic ingredient, not an approved drug; injectable form is an unapproved research chemical. GHK-Cu (INCI “Copper Tripeptide-1”) is an established, legal topical cosmetic ingredient, used for decades in creams and serums for skin firmness, wound repair and hair products; in that context it has a long safety record. It is not approved by the FDA, EMA, TGA or any other major regulator as a drug or dietary supplement for any therapeutic (systemic) indication, and there is no USP/NF drug monograph. The injectable/systemic “research peptide” GHK-Cu now sold online is a different matter: it is an unapproved research chemical, marketed “for research use only / not for human consumption,” with no regulatory oversight of the systemic product. GHK-Cu is not a DEA-controlled substance. It is also not currently on the WADA Prohibited List in its own right (unlike some growth-factor peptides), but athletes should verify current status before use.

How it’s supplied & administered. Two very different supply chains exist. (1) Cosmetic: finished creams, serums and gels containing low percentages of copper tripeptide — the mainstream, low-risk form, applied topically. (2) Research peptide: a lyophilized (freeze-dried) blue-tinted powder (the copper gives it color), sold in vials, requiring reconstitution (typically with bacteriostatic or sterile water) for subcutaneous or intramuscular injection. Reconstituted peptide is refrigerated, protected from light and used within weeks; unreconstituted powder is stored cold. A recurring formulation problem even in cosmetics is skin penetration — the intact charged tripeptide crosses the stratum corneum poorly, so delivery systems (encapsulation, penetration enhancers) are an active area of work.

Sourcing reality (this is a safety issue, not a footnote). For the cosmetic form from reputable manufacturers, quality is generally reliable. For the injectable research-peptide form, essentially all supply comes from unregulated vendors with no manufacturing oversight; independent testing of gray-market peptides repeatedly finds mislabeled content, under- or over-dosing, degraded peptide and contaminants. For an injected product the specific hazards are bacterial endotoxin, microbial contamination and residual synthesis solvents, none assessable without a genuine third-party certificate of analysis (COA) with HPLC purity and endotoxin testing. Reconstitution and self-injection by non-clinicians add sterility and dosing-error risk. This page does not recommend, rank or link any vendor; purity and identity are unverifiable in the research-chemical market.

Safety

GHK-Cu’s safety profile is bimodal by route — topical cosmetic use has a long, benign record, while the injectable form sold as a research peptide is essentially unstudied in humans. The cosmetic record does not transfer.

Safety at a Glance

❔ Toxicity unknown

• Topical cosmetic use is well tolerated. GHK is endogenous to human plasma, and adverse effects are uncommon and minor local irritation.
• Injectable/systemic use is essentially unstudied in humans. No dose-finding trial, no safety trial, and no established dose-limiting effect.
• Wilson’s disease and other copper-metabolism disorders. GHK carries copper into cells, so repeated systemic dosing raises a theoretical copper-overload concern.
• Not assessed in pregnancy or breastfeeding. Avoid the systemic form — see the box below.
• Copper supplements. A plausible additive effect, and the only mechanistically grounded interaction flag; everything else is unassessed.
• Injection and sourcing risks. Non-sterile technique, endotoxin from impure product, injection-site infection and dosing error.

Full Safety & Interactions Detail

Overall posture. GHK-Cu’s safety profile is bimodal by route. Topical/cosmetic use has a long, benign track record and the peptide is endogenous (naturally present in human plasma), so at the low concentrations used in skincare it is generally well tolerated. Systemic/injectable use is essentially unstudied in humans — there is no dose-finding or safety trial for injected GHK-Cu — so its systemic safety cannot be asserted from the cosmetic record. Pickart’s reviews describe GHK as nontoxic at the nanomolar concentrations at which it is biologically active ^{1Reference 1Pickart L · 2018ReviewRegenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data — reviewView study →}.

Adverse effects. Topically: uncommon and minor (local irritation/sensitivity in some users). Systemically: not characterized in humans. Mechanistic/class concerns for systemic dosing center on copper: because GHK carries copper into cells, repeated systemic administration raises a theoretical copper-overload concern (relevant especially to anyone with Wilson’s disease or impaired copper handling), and copper balance interactions are plausible but unquantified.

Dose-limiting effect. None established in humans (no systemic dose-finding trial exists).

Interactions. No human interaction studies. The mechanistically-grounded flag is copper homeostasis — theoretical additive effect with copper supplements and caution in disorders of copper metabolism (Wilson’s disease). All other interactions are unassessed.

Injection-specific risks. For the research-peptide route: non-sterile technique, contamination/endotoxin from impure product, injection-site reaction/infection and dosing error — often larger real-world hazards than the peptide’s own pharmacology.

Who should avoid it (systemic form). People with Wilson’s disease or other copper-metabolism disorders, pregnant or breastfeeding individuals, and anyone considering the injectable form outside a supervised clinical trial. The conservative position is that the systemic/injectable form should not be self-administered given the absence of human safety data; the topical cosmetic form is low-risk for general use.

Scope — what is and is not covered:

• Human data? Cosmetic/topical only, and limited — two small human RCTs (laser-resurfacing cosmetic, positive only on patient-reported outcomes; venous ulcer, null), plus uncontrolled cosmetic testing. No human trial of the injectable/systemic form; a Phase 2 topical wound-healing RCT began recruiting in 2026.
• Interactions assessed? No in humans; only a mechanistic copper-homeostasis flag.
• Pregnancy/lactation assessed? No — not established; avoid the systemic form.
• Long-term safety established? Topical: long cosmetic use record. Systemic/injectable: No — no long-term human data; do not infer systemic safety from the topical record.

Never imply safety from silence. The topical cosmetic safety record does not transfer to the injectable/systemic form, which is unstudied in humans — for that route the honest statement is “not assessed.”

Pregnancy & Lactation

? Not established in pregnancy? Not established in lactation

Not assessed / not established. There are no human pregnancy or lactation data for administered GHK-Cu and no adequate reproductive-safety studies; topical cosmetic exposure is widespread and not associated with known harm, but the injectable/systemic form should be avoided in pregnancy and breastfeeding.

Dosage

There is no established therapeutic or supplement dose for GHK-Cu, and nothing here is a dosing recommendation. In cosmetics it is formulated topically at low percentages of copper tripeptide in creams and serums — a formulation figure, not a dose. No validated systemic or injectable human dose exists: the injectable “research peptide” regimens circulating online are not derived from controlled human trials, have no dose-finding or safety basis, and are stated here only to be clear that they are unvalidated. The one modern controlled human trial now recruiting uses a topical gel ^{28Reference 28ClinicalTrials.gov · 2026RCTTopical GHK-Cu Gel for Acute Skin Wound Healing — Phase 2, randomised, placebo-controlled (recruiting; started Feb 2026). https://clinicaltrials.gov/study/NCT07437586View study →}; there is no established systemic route. This entry is informational only and is not an endorsement of use.

References

1. Pickart L, Margolina A (2018). Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data — review. Int J Mol Sci. https://pubmed.ncbi.nlm.nih.gov/29986520/
2. Pickart L, Vasquez-Soltero JM, Margolina A (2015). GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration — review. Biomed Res Int. https://pubmed.ncbi.nlm.nih.gov/26236730/
3. Pickart L, Vasquez-Soltero JM, Margolina A (2014). GHK and DNA: resetting the human genome to health — review. Biomed Res Int. https://pubmed.ncbi.nlm.nih.gov/25302294/
4. Maquart FX, Pickart L, et al. (1988). Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu²⁺ — in vitro. FEBS Lett. https://pubmed.ncbi.nlm.nih.gov/3169264/
5. Parker NP, Ardeshirpour F, et al. (2013). Effects of topical copper tripeptide complex on wound healing in an irradiated rat model — rat/in vivo. Otolaryngol Head Neck Surg. https://pubmed.ncbi.nlm.nih.gov/23744835/
6. Miller TR, Wagner JD, et al. (2006). Effects of topical copper tripeptide complex on CO₂ laser-resurfaced skin — randomised controlled trial (human). Arch Facial Plast Surg. https://pubmed.ncbi.nlm.nih.gov/16847171/
7. Cangul IT, Gul NY, et al. (2006). Evaluation of the effects of topical tripeptide-copper complex and zinc oxide on open-wound healing in rabbits — randomised (rabbit). Vet Dermatol. https://pubmed.ncbi.nlm.nih.gov/17083573/
8. Bishop JB, Phillips LG, et al. (1992). A prospective randomized evaluator-blinded trial of two potential wound healing agents for the treatment of venous stasis ulcers — RCT (human; null for copper tripeptide). J Vasc Surg. https://pubmed.ncbi.nlm.nih.gov/1495150/
9. Pickart L, Thaler MM (1973). Tripeptide in human serum which prolongs survival of normal liver cells and stimulates growth in neoplastic liver — discovery. Nat New Biol. https://pubmed.ncbi.nlm.nih.gov/4349963/
10. Pickart L, Vasquez-Soltero JM, Margolina A (2012). The human tripeptide GHK-Cu in prevention of oxidative stress and degenerative conditions of aging: implications for cognitive health — review. Oxid Med Cell Longev. https://pubmed.ncbi.nlm.nih.gov/22666519/
11. Pickart L, Vasquez-Soltero JM, Margolina A (2017). The Effect of the Human Peptide GHK on Gene Expression Relevant to Nervous System Function and Cognitive Decline — in silico/in vitro. Brain Sci. https://pubmed.ncbi.nlm.nih.gov/28212278/
12. Ma WH, Li M, et al. (2020). Protective effects of GHK-Cu in bleomycin-induced pulmonary fibrosis via anti-oxidative stress and anti-inflammation pathways — mouse. Life Sci. https://pubmed.ncbi.nlm.nih.gov/31809714/
13. Zhou XM, Wang GL, et al. (2017). GHK Peptide Inhibits Bleomycin-Induced Pulmonary Fibrosis in Mice by Suppressing TGFβ1/Smad-Mediated Epithelial-to-Mesenchymal Transition — mouse. Front Pharmacol. https://pubmed.ncbi.nlm.nih.gov/29311918/
14. Park JR, Lee H, et al. (2016). The tri-peptide GHK-Cu complex ameliorates lipopolysaccharide-induced acute lung injury in mice — mouse/in vitro. Oncotarget. https://pubmed.ncbi.nlm.nih.gov/27517151/
15. Bian Y, Deng M, et al. (2024). The glycyl-L-histidyl-L-lysine-Cu²⁺ complex attenuates silica-induced lung inflammation and fibrosis via peroxiredoxin-6 — mouse. Redox Biol. https://pubmed.ncbi.nlm.nih.gov/38879894/
16. Pickart L (2008). The human tri-peptide GHK and tissue remodeling — review. J Biomater Sci Polym Ed. https://pubmed.ncbi.nlm.nih.gov/18644225/
17. Philips N, Hwang H, et al. (2010). Stimulation of cell proliferation and expression of matrixmetalloproteinase-1 and interleukin-8 genes in dermal fibroblasts by copper — in vitro. Connect Tissue Res. https://pubmed.ncbi.nlm.nih.gov/20053132/
18. Philips N, Samuel P, et al. (2012). Beneficial regulation of fibrillar collagens, HSP-47, elastin fiber components, TGF-β1, VEGF and oxidative stress effects by copper in dermal fibroblasts — in vitro. Connect Tissue Res. https://pubmed.ncbi.nlm.nih.gov/22324999/
19. Beretta G, Arlandini E, et al. (2008). Acrolein sequestering ability of the endogenous tripeptide glycyl-histidyl-lysine (GHK) — in vitro. J Pharm Biomed Anal. https://pubmed.ncbi.nlm.nih.gov/18378108/
20. Ogen-Shtern N, Chumin K, et al. (2020). Increased pro-collagen 1, elastin, and TGF-β1 expression by copper ions in an ex-vivo human skin model — ex-vivo human skin. J Cosmet Dermatol. https://pubmed.ncbi.nlm.nih.gov/31603269/
21. Gruchlik A, Chodurek E, et al. (2014). Effect of Gly-His-Lys and its copper complex on TGF-β secretion in normal human dermal fibroblasts — in vitro. Acta Pol Pharm. https://pubmed.ncbi.nlm.nih.gov/25745767/
22. Mortazavi SM, Mohammadi Vadoud SA, et al. (2025). Topically applied GHK as an anti-wrinkle peptide: advantages, problems and prospective — review. BioImpacts. https://pubmed.ncbi.nlm.nih.gov/39963574/
23. Wang JV, Hattier G, et al. (2021). Tripeptide/Hexapeptide Topical in Esthetics: Evidence behind the Skincare Formulation — review. Skinmed. https://pubmed.ncbi.nlm.nih.gov/33938433/
24. Mortazavi SM, Moghimi HR (2022). Skin permeability, a dismissed necessity for anti-wrinkle peptide performance — review. Int J Cosmet Sci. https://pubmed.ncbi.nlm.nih.gov/35302659/
25. Kuceki G, Coppinger AJ, et al. (2025). Enhanced hair regrowth with five monthly sessions of minoxidil-dutasteride-copper peptides tattooing for androgenetic alopecia — human (combination therapy). JAAD Int. https://pubmed.ncbi.nlm.nih.gov/40225275/
26. Hu J, Zhang C, et al. (2026). Glycyl-L-histidyl-L-lysine-Cu²⁺ (GHK-Cu) attenuates CuSO₄- or LPS-induced inflammation — in vitro/animal. Eur J Pharmacol. https://pubmed.ncbi.nlm.nih.gov/41997403/
27. Mendias CL, Awan TM, et al. (2026). Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance — review. Sports Med. https://pubmed.ncbi.nlm.nih.gov/41966639/
28. ClinicalTrials.gov (2026). Topical GHK-Cu Gel for Acute Skin Wound Healing — Phase 2, randomised, placebo-controlled (recruiting; started Feb 2026). https://clinicaltrials.gov/study/NCT07437586
29. ClinicalTrials.gov (2027, planned). Two-Part Study of the Effects of the X39 Patch on Circulating GHK and GHK-Cu Levels in Healthy Adults — not yet recruiting. https://clinicaltrials.gov/study/NCT07706361

View all 29 references▾